Literature DB >> 23838178

Molecular MRI of collagen to diagnose and stage liver fibrosis.

Bryan C Fuchs1, Huifang Wang, Yan Yang, Lan Wei, Miloslav Polasek, Daniel T Schühle, Gregory Y Lauwers, Ashfaq Parkar, Anthony J Sinskey, Kenneth K Tanabe, Peter Caravan.   

Abstract

BACKGROUND & AIMS: The gold standard in assessing liver fibrosis is biopsy despite limitations like invasiveness and sampling error and complications including morbidity and mortality. Therefore, there is a major unmet medical need to quantify fibrosis non-invasively to facilitate early diagnosis of chronic liver disease and provide a means to monitor disease progression. The goal of this study was to evaluate the ability of several magnetic resonance imaging (MRI) techniques to stage liver fibrosis.
METHODS: A gadolinium (Gd)-based MRI probe targeted to type I collagen (termed EP-3533) was utilized to non-invasively stage liver fibrosis in a carbon tetrachloride (CCl4) mouse model and the results were compared to other MRI techniques including relaxation times, diffusion, and magnetization transfer measurements.
RESULTS: The most sensitive MR biomarker was the change in liver:muscle contrast to noise ratio (ΔCNR) after EP-3533 injection. We observed a strong positive linear correlation between ΔCNR and liver hydroxyproline (i.e. collagen) levels (r=0.89) as well as ΔCNR and conventional Ishak fibrosis scoring. In addition, the area under the receiver operating curve (AUR0C) for distinguishing early (Ishak ≤ 3) from late (Ishak ≥ 4) fibrosis was 0.942 ± 0.052 (p<0.001). By comparison, other MRI techniques were not as sensitive to changes in fibrosis in this model.
CONCLUSIONS: We have developed an MRI technique using a collagen-specific probe for diagnosing and staging liver fibrosis, and validated it in the CCl4 mouse model. This approach should provide a better means to monitor disease progression in patients.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ADC; AUROC; CCl(4); CNR; ELF; EP-3533; Fibrosis; Gadolinium; Gd; HCC; MR elastography; MRE; MRI; MTR; Molecular imaging; Non-invasive; ROC; SD; SI; SL; TE; TI; Type 1 collagen; apparent diffusion coefficient; area under the ROC; carbon tetrachloride; contrast to noise ratio; echo time; enhanced liver fibrosis; gadolinium; hepatocellular carcinoma; intravenous; inversion time; iv; magnetic resonance imaging; magnetization transfer ratio; receiver operating curve; signal intensity; spin lock time; standard deviation

Mesh:

Substances:

Year:  2013        PMID: 23838178      PMCID: PMC3805694          DOI: 10.1016/j.jhep.2013.06.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  29 in total

1.  Collagen-targeted MRI contrast agent for molecular imaging of fibrosis.

Authors:  Peter Caravan; Biplab Das; Stéphane Dumas; Frederick H Epstein; Patrick A Helm; Vincent Jacques; Steffi Koerner; Andrew Kolodziej; Luhua Shen; Wei-Chuan Sun; Zhaoda Zhang
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

Review 2.  Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography.

Authors:  Massimo Pinzani; Francesco Vizzutti; Umberto Arena; Fabio Marra
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-02

3.  Serum markers detect the presence of liver fibrosis: a cohort study.

Authors:  William M C Rosenberg; Michael Voelker; Robert Thiel; Michael Becka; Alastair Burt; Detlef Schuppan; Stefan Hubscher; Tania Roskams; Massimo Pinzani; Michael J P Arthur
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

4.  Magnetization transfer contrast imaging in Niemann pick type C mouse liver.

Authors:  Jingyu Guo; Robert Erickson; Theodore Trouard; Jean-Philippe Galons; Robert Gillies
Journal:  J Magn Reson Imaging       Date:  2003-09       Impact factor: 4.813

5.  Bleeding complications after percutaneous liver biopsy. An analysis of risk factors.

Authors:  Birgit Terjung; Isabelle Lemnitzer; Franz Ludwig Dumoulin; Wolfgang Effenberger; Hans Hermann Brackmann; Tilman Sauerbruch; Ulrich Spengler
Journal:  Digestion       Date:  2003       Impact factor: 3.216

6.  Assessment of hepatic fibrosis with magnetic resonance elastography.

Authors:  Meng Yin; Jayant A Talwalkar; Kevin J Glaser; Armando Manduca; Roger C Grimm; Phillip J Rossman; Jeff L Fidler; Richard L Ehman
Journal:  Clin Gastroenterol Hepatol       Date:  2007-10       Impact factor: 11.382

Review 7.  Evaluation of liver fibrosis: a concise review.

Authors:  Nezam H Afdhal; David Nunes
Journal:  Am J Gastroenterol       Date:  2004-06       Impact factor: 10.864

8.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

Authors:  Laurent Sandrin; Bertrand Fourquet; Jean-Michel Hasquenoph; Sylvain Yon; Céline Fournier; Frédéric Mal; Christos Christidis; Marianne Ziol; Bruno Poulet; Farad Kazemi; Michel Beaugrand; Robert Palau
Journal:  Ultrasound Med Biol       Date:  2003-12       Impact factor: 2.998

Review 9.  Liver cirrhosis.

Authors:  Detlef Schuppan; Nezam H Afdhal
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

Review 10.  Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ.

Authors:  John P Iredale
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

View more
  61 in total

1.  Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.

Authors:  Daniel L Motola; Peter Caravan; Raymond T Chung; Bryan C Fuchs
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

Review 2.  Advances in functional and molecular MRI technologies in chronic liver diseases.

Authors:  Iris Y Zhou; Onofrio A Catalano; Peter Caravan
Journal:  J Hepatol       Date:  2020-06-22       Impact factor: 25.083

3.  Elastin imaging enables noninvasive staging and treatment monitoring of kidney fibrosis.

Authors:  Qinxue Sun; Maike Baues; Barbara M Klinkhammer; Josef Ehling; Sonja Djudjaj; Natascha I Drude; Christoph Daniel; Kerstin Amann; Rafael Kramann; Hyojin Kim; Julio Saez-Rodriguez; Ralf Weiskirchen; David C Onthank; Rene M Botnar; Fabian Kiessling; Jürgen Floege; Twan Lammers; Peter Boor
Journal:  Sci Transl Med       Date:  2019-04-03       Impact factor: 17.956

Review 4.  Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel.

Authors:  Jeanne M Horowitz; Sudhakar K Venkatesh; Richard L Ehman; Kartik Jhaveri; Patrick Kamath; Michael A Ohliger; Anthony E Samir; Alvin C Silva; Bachir Taouli; Michael S Torbenson; Michael L Wells; Benjamin Yeh; Frank H Miller
Journal:  Abdom Radiol (NY)       Date:  2017-08

Review 5.  Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.

Authors:  Natalie J Torok; Jonathan A Dranoff; Detlef Schuppan; Scott L Friedman
Journal:  Hepatology       Date:  2015-03-10       Impact factor: 17.425

Review 6.  The significance of YKL-40 protein in liver fibrosis.

Authors:  Hui Tao; Jing-Jing Yang; Kai-Hu Shi; Cheng Huang; Lei Zhang; Xiong-Wen Lv; Jun Li
Journal:  Inflamm Res       Date:  2014-01-19       Impact factor: 4.575

7.  Molecular imaging of oxidized collagen quantifies pulmonary and hepatic fibrogenesis.

Authors:  Howard H Chen; Philip A Waghorn; Lan Wei; Luis F Tapias; Daniel T Schühle; Nicholas J Rotile; Chloe M Jones; Richard J Looby; Gaofeng Zhao; Justin M Elliott; Clemens K Probst; Mari Mino-Kenudson; Gregory Y Lauwers; Andrew M Tager; Kenneth K Tanabe; Michael Lanuti; Bryan C Fuchs; Peter Caravan
Journal:  JCI Insight       Date:  2017-06-02

Review 8.  Pathobiology of liver fibrosis: a translational success story.

Authors:  Youngmin A Lee; Michael C Wallace; Scott L Friedman
Journal:  Gut       Date:  2015-02-13       Impact factor: 23.059

Review 9.  Molecular imaging of fibrosis: recent advances and future directions.

Authors:  Sydney B Montesi; Pauline Désogère; Bryan C Fuchs; Peter Caravan
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

Review 10.  Advances in gadolinium-based MRI contrast agent designs for monitoring biological processes in vivo.

Authors:  Jacques Lux; A Dean Sherry
Journal:  Curr Opin Chem Biol       Date:  2018-05-09       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.